Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

497 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cytokine Profiling of End Stage Cancer Patients Treated with Immunotherapy.
Merlano MC, Abbona A, Paccagnella M, Falletta A, Granetto C, Ricci V, Fea E, Denaro N, Ruatta F, Merlotti A, Bertetto O, Crosetto N, Galizia D, Basiricò M, Gammaitoni L, Sangiolo D, Aglietta M, Garrone O. Merlano MC, et al. Among authors: ricci v. Vaccines (Basel). 2021 Mar 8;9(3):235. doi: 10.3390/vaccines9030235. Vaccines (Basel). 2021. PMID: 33800511 Free PMC article.
Heterogeneity of colon cancer: from bench to bedside.
Merlano MC, Granetto C, Fea E, Ricci V, Garrone O. Merlano MC, et al. Among authors: ricci v. ESMO Open. 2017 Aug 22;2(3):e000218. doi: 10.1136/esmoopen-2017-000218. eCollection 2017. ESMO Open. 2017. PMID: 29209524 Free PMC article. Review.
Evaluation of antibody-dependent cell-mediated cytotoxicity activity and cetuximab response in KRAS wild-type metastatic colorectal cancer patients.
Lo Nigro C, Ricci V, Vivenza D, Monteverde M, Strola G, Lucio F, Tonissi F, Miraglio E, Granetto C, Fortunato M, Merlano MC. Lo Nigro C, et al. Among authors: ricci v. World J Gastrointest Oncol. 2016 Feb 15;8(2):222-30. doi: 10.4251/wjgo.v8.i2.222. World J Gastrointest Oncol. 2016. PMID: 26909137 Free PMC article.
DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer.
Cremolini C, Del Re M, Antoniotti C, Lonardi S, Bergamo F, Loupakis F, Borelli B, Marmorino F, Citi V, Cortesi E, Moretto R, Ronzoni M, Tomasello G, Zaniboni A, Racca P, Buonadonna A, Allegrini G, Ricci V, Di Donato S, Zagonel V, Boni L, Falcone A, Danesi R. Cremolini C, et al. Among authors: ricci v. Oncotarget. 2017 Dec 21;9(8):7859-7866. doi: 10.18632/oncotarget.23559. eCollection 2018 Jan 30. Oncotarget. 2017. PMID: 29487697 Free PMC article.
497 results